Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country

INTRODUCTION: Immune checkpoint inhibitor (ICI) therapy is an established treatment for advanced non‐small‐cell lung cancer (NSCLC) and programmed death ligand‐1 (PD‐L1) expression is a recognized biomarker to determine response to therapy. We retrospectively analyzed NSCLC patients in the Malaysia...

Descripción completa

Detalles Bibliográficos
Autores principales: How, Soon Hin, Tho, Lye Mun, Liam, Chong Kin, Hasbullah, Harissa H., Ho, Gwo Fuang, Muhammad Nor, Ibtisam, Poh, Mau Ern, Ho, Kean Fatt, Thiagarajan, Muthukkumaran, Samsudin, Azlina, Omar, Azza, Ong, Choo Khoon, Pang, Yong Kek, Soon, Sing Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161340/
https://www.ncbi.nlm.nih.gov/pubmed/35502623
http://dx.doi.org/10.1111/1759-7714.14442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161340/
https://www.ncbi.nlm.nih.gov/pubmed/35502623
http://dx.doi.org/10.1111/1759-7714.14442

Ejemplares similares